LENZ Therapeutics concludes merger with Graphite Bio

22 Mar 2024
www.pharmaceutical-technology.com
Phase 3Clinical ResultAcquisitionOrphan DrugExecutive Change
LENZ Therapeutics concludes merger with Graphite Bio
Preview
Source: Pharmaceutical Technology
LENZ Therapeutics’s focus will be on advancing presbyopia treatments post-merger. Credit: Prostock-studio / Shutterstock.com.
LENZ Therapeutics has concluded its merger with Graphite Bio, forming a late-stage biopharmaceutical company dedicated to developing treatments for presbyopia.
The merger, an all-stock transaction agreed by the companies in November 2023, positions the combined entity under the name LENZ Therapeutics.
The combined company will focus on advancing the lead assets of LENZ Therapeutics for presbyopia treatment.
With $225m in cash or cash equivalents, the company is poised to build infrastructure and commercialise its lead product candidates, pending Phase III trial outcomes and Food and Drug Administration (FDA) approval.
The financial foundation of the merged company includes $53.5m from a concurrent private investment in public equity financing, contributed by a syndicate of healthcare investors.
See Also:
FDA grants orphan drug status to HI-Bio’s felzartamab for AMR
LENZ Therapeutics concludes merger with Graphite Bio
Preview
Source: Pharmaceutical Technology
LENZ Therapeutics concludes merger with Graphite Bio
Preview
Source: Pharmaceutical Technology
LENZ’s existing investors led the syndicate, which also saw participation from new investors.
Eef Schimmelpennink will lead the company as president and CEO, steering it towards its goal of treating a broad demographic of patients with presbyopia.
The product candidates of LENZ are LNZ100 and LNZ101, which are preservative-free, single-use, once-a-day eye drops.
The drops containing aceclidine and a combination of aceclidine plus brimonidine have shown promising results in terms of quick onset and sustained near-vision improvement.
The treatments have also demonstrated effectiveness across a wide age and refractive range of presbyopes without compromising distance vision.
Based on the data from the Phase III CLARITY trials, the company plans to file a new drug application with the FDA by mid-2024.
LENZ’s strategy is to commercialise the most effective product for the widest range of presbyopes tested, intending to launch either LNZ100 or LNZ101 in the US through its own commercial organisation.
Schimmelpennink stated: “Following the close of this transaction, we believe we are well-positioned to bring the opportunity of a once-daily pharmacological eye drop intended to improve near vision throughout the full workday closer to the 128 million people in the United States who are impacted by presbyopia.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.